Yttrium Y 90 ibritumomab tiuxetan

Yttrium Y 90 ibritumomab tiuxetan, also known as IDEC-Y2B8 monoclonal antibody, is an anticancer drug. It is a combination of the radioisotope yttrium-90 and a monoclonal antibody, a produced substance that can locate and bind to cancer cells. Once attached to a cell, it can either kill it or deliver radioactive cancer-killing substances to it without harming normal cells.

The National Cancer Institute is currently researching how effective this drug works in treating patients with progressive non-Hodgkin's lymphoma.